The Phase I results are in for our glioblastoma clinical trial

Rocks are stacked from largest to smallest with golden rays of sunlight slanting past. Behind them in a soft focus, the sun sinks into the sea.

It all stacks up — results from our Phase I clinical trial suggest our treatment could improve outcomes for patients with glioblastoma.

Results of our Phase I clinical trial on glioblastoma, a severe brain cancer, show that the our treatment is safe with minimal side effects, preserves patients’ quality of life, and could extend life expectancy. We’re seeking more funding to start our glioblastoma Phase II clinical trial, where we plan to treat more patients at an earlier stage in their illness.

Our treatment is safe and preserves patients’ quality of life

Glioblastoma is a deadly form of brain cancer. The cancer and its conventional treatment can severely impact patients’ quality of life. Our Phase I clinical trial shows that our treatment is safe with minimal side effects, and preserves patients’ quality of life during treatment. Our treatment consisted of a combination of low-cost common medications that can be taken orally at home.

Read more about how our proposed method of treatment works  

Our Phase I clinical trial enrolled patients with recurrent glioblastoma who had exhausted conventional treatment options. In our proposed Phase II clinical trial we’ll recruit 75 patients, and start treatment at an earlier stage of the cancer.

Our treatment may increase life expectancy of patients with glioblastoma

Analysis of results of our glioblastoma Phase I clinical trial shows that it may improve life expectancy of the patients.

The overall median survival of patients with glioblastoma is 14.6 months following conventional treatment. Our Phase I clinical trial shows a median survival time of 20 months. These results are encouraging and the Independent Data Monitoring Board has recommended a Phase II clinical trial, to allow further assessment of outcomes.

Who will be recruited for our Phase II clinical trial

We’ll recruit 75 patients including Māori, Pasifika, and other disadvantaged minority communities, for the study.

We need more funding before we can start

We’re actively seeking funding from existing and prospective new supporters and funding bodies so we can begin our Phase II clinical trial. The funding we need is beyond our present resources and the support we’ve had from our generous donors over the years.

We’re very thankful for the wonderful support we’ve received along the way. We’re excited to see the results the Phase II glioblastoma clinical trial brings!

How to donate

We’re always looking for philanthropic, business, and other donations so we can continue our important work. You can make one-off or regular donations, or you could consider making us a beneficiary of your estate or family trust.


Make a donation